Updated:
Xeraya Capital
Xeraya Capital was established in 2006 as a laboratory for direct venture and growth-equity investments under the Khazanah Nasional umbrella.
Xeraya Capital
Xeraya Capital was established in 2006 as a laboratory for direct venture and growth-equity investments under the Khazanah Nasional umbrella. Khazanah, Malaysia's sovereign wealth fund, seeded the platform to capture innovation returns beyond public markets and traditional infrastructure. Managing Director Fauzi Zulkifli has stewarded the firm from its inception, building a portfolio that operates at the intersection of deep technology and national strategic interests. The firm pursues a hybrid strategy, blending early-stage venture with growth-equity and expansion-stage positions. Core sectors include life sciences — with confirmed positions in medical device and biotech companies including Singapore-based EndoMaster (per the firm's official communications) — alongside renewable energy and advanced materials. Xeraya has backed utility-scale solar developers and next-generation battery technology platforms, often as a lead or co-lead investor across Southeast Asia and North America. The fund construction favors direct equity stakes rather than LP commitments, though the firm has co-invested alongside global GPs in cross-border life sciences deals. Team size remains undisclosed, and the firm operates without additional offices outside Kuala Lumpur. Xeraya's structural proximity to Khazanah provides a distinctly patient capital base, but also subjects it to the governance rhythms of a sovereign entity. In recent years, the firm has navigated leadership transitions within Khazanah itself, which in 2021 brought in a new managing director for the parent fund (per Reuters, 2021). How that shift recalibrates Xeraya's mandate or independence remains a live question for allocators tracking the vehicle. Xeraya's structural differentiator is its sovereign-linked balance sheet applied to venture-stage risk. Unlike most SWF direct-investment arms that focus on late-stage or pre-IPO deals, Xeraya enters at Series A and B in sectors — biotech, deep tech — where sovereign capital rarely sits. It functions as a policy-aware venture platform, accountable to a national development mandate yet competing for allocations against pure financial-return vehicles, a tension that shapes its entire portfolio construction.
General information
Firm type
Private Equity
Year founded
2006
AUM
Undisclosed
Location
Region
Asia
Country
Malaysia
City
Kuala Lumpur
Corporate office
Kuala Lumpur, Malaysia
Principals
Fauzi Zulkifli
Managing Director
Sector focus
Frequently asked questions
Who runs investment decisions at Xeraya Capital?
Fauzi Zulkifli serves as the Managing Director and has led the firm since its founding in 2006. The investment committee structure involves senior members of the Xeraya team, with ultimate governance tied to its sponsor, Khazanah Nasional, as the sole LP. Specific IC members beyond Zulkifli are not publicly disclosed.
How is Xeraya Capital related to Khazanah Nasional?
Xeraya Capital was established as a wholly owned, dedicated venture and growth-investment arm of Khazanah Nasional, Malaysia's sovereign wealth fund. This structure means Xeraya operates with a single-LP balance sheet rather than raising external third-party capital, giving it a sovereign-patience advantage but also aligning it with Khazanah's strategic economic development goals.
Does Xeraya participate in fund commitments or only direct deals?
Xeraya primarily executes direct equity investments, leading or co-leading rounds in growth-stage and venture-backed companies. While its core model is direct, the firm has co-invested alongside other GPs in cross-border deals, particularly in life sciences, but it does not market itself as a fund-of-funds or LP capital allocator in the traditional sense.
What investment stages does Xeraya typically target?
The firm deploys across the venture and growth-equity spectrum, with confirmed activity from Series A rounds through to expansion-stage industrial and healthcare investments. The hybrid mandate allows it to hold positions from early commercial validation through to pre-IPO stages without fixed-stage allocation buckets.
Which geographies does Xeraya cover?
Xeraya invests across Southeast Asia and North America, with a portfolio that includes Singapore-based biotechs alongside US life sciences and clean energy companies. The firm does not publicly limit itself to Malaysian-headquartered assets, distinguishing it from some domestically focused sovereign vehicles.
Which sectors does Xeraya Capital actively invest in?
The firm's disclosed focus spans life sciences, medical devices, renewable energy, advanced materials, and industrial technology. Confirmed sub-sectors include biotech, utility-scale solar, and battery technology. The thesis connects these verticals through a shared requirement for patient, science-heavy capital that aligns with sovereign timelines.
What is Xeraya's known posture on leading rounds versus co-investing?
Xeraya is willing to lead or co-lead rounds in its core sectors, particularly on its home turf in Southeast Asia. In North American life sciences deals, it more frequently co-invests alongside established domain-specialist VCs, using its sovereign balance sheet to anchor rounds rather than originate them independently.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: